For Consumers

FDA Office of Women's Health Update Archive

 

 

The words e-update with blue background

The Office of Women's Health e-Update highlights women's health initiatives, meetings, and regulatory safety information from the U.S. Food and Drug Administration (FDA). The e-Update is disseminated via email to the public.

Current Issue:  February 2015

Message from the Director

Heart disease in women is a top priority for the Office of Women’s Health. We fund research that has helped shape FDA guidance to industry and advanced knowledge about the diagnosis and treatment of cardiovascular diseases in women. We also conduct outreach campaigns to disseminate FDA safety alerts and easy-to-read publications to women in diverse communities nationwide. I encourage you to visit our Heart Disease Research and Heart Health for Women webpages to learn more about the work being done at OWH and across the Agency.  Look to us over the coming year for new opportunities to collaborate on this important issue.

Marsha Henderson - Assistant Commissioner for Women’s Health

***********************************

Heart Resources for Women 

 

FDA has digital tools and easy-to-read publications on heart health for women. Throughout February, help spread the word about these resources and encourage the women in your community to live heart healthy lives.

***********************************

New OWH Publications on Sex Differences and Clinical Trials

 

The Office of Women’s Health Research and Development Program conducts studies to assess the participation of women in clinical trials in support of FDA product applications and collaborates with FDA centers and external partners to understand the impact of sex differences on response to therapy. In support of these efforts, FDA staff authored to recent publications:

  • Eshera, N., Itana, H, Zhang, L., Soon, G.,  Fadiran E.O Demographics of Clinical Trials Participants in Pivotal Clinical Trials for New Molecular Entity Drugs and Biologics Approved by FDA from 2010 to 2012. American Journal of Therapeutics, 0, 1-21. 2015. [Epub ahead of print] Eshera et al. provided an update on the demographics of clinical trial participants and on the conduct of sex analyses for New Molecular Entity drugs and biologics approved by FDA between 2010 and 2012 in terms of sex, age and race, and notably found that the inclusion of women was generally comparable to their prevalence in the disease population.

  • Fadiran, E.O., Zhang, L. (2015) Effects of Sex Differences in the Pharmacokinetics of Drugs and Their Impact on the Safety of Medicines in Women. M. Harrison-Woolrych (e.d) Medicines in Women.  (pp. 41-68) This book chapter provides a comprehensive understanding of sex differences in drug pharmacokinetics and of the resulting impacts on drug safety for women.

     

***********************************

Breast Cancer Public Meeting 

 

On April 2, 2015, FDA will be conducting a public meeting on Breast Cancer Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of breast cancer on daily life and patients’ views on currently available therapies to treat the condition. Registration will close on March 23, 2015.

**********************************

Extras

 

FDA Commentary on Medscape Highlights Pregnancy Labeling

Medscape posted an interview with FDA experts Melissa S. Tassinari and Jeanine Best, on how the new pregnancy and lactation labeling will help providers make more informed decisions about treatments for pregnant and breastfeeding patients. The interview is a part of a series of commentaries from FDA experts that are designed to improve communication between FDA and clinicians. 

**********************************

Consumer Article on Overactive Bladder Treatments

People with overactive bladder have a bladder muscle that squeezes too often or squeezes without warning. Download and share the new consumer update on FDA-approved treatments that can help control overactive bladder symptoms.

**********************************

FDA Meetings

Public Conference: The Importance of Getting It Right – How to Measure and Interpret Drug-Induced Liver Injury Information and Make Correct Diagnoses

March 18-19, 2015

College Park Marriott Hotel and Conference Center, Hyattsville, MD

 ___________________________________________________________________

 

Past OWH e-Update Issues

Contact FDA

301-796-9440
Fax:301-847-8604
Food and Drug Administration Office of Women's Health

10903 New Hampshire Avenue

WO32-2333

Silver Spring, MD 20993

Page Last Updated: 02/06/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.